Loading clinical trials...
Loading clinical trials...
A Phase Ib Single-arm, Open-label, Multicenter Study to Assess the Safety and Tolerability of Combined Treatment With Nilotinib 300mg BID and Ruxolitinib Increasing Dose in CML and Ph+ ALL Patients
Conditions
Interventions
Nilotinib
Ruxolitinib
Locations
4
Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Jena, Germany
Novartis Investigative Site
Leipzig, Germany
Start Date
February 18, 2015
Primary Completion Date
March 6, 2018
Completion Date
April 3, 2018
Last Updated
May 1, 2019
NCT06994676
NCT06523556
NCT06236724
NCT04195633
NCT05334069
NCT05362773
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions